January 27th 2025
A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.
Merck, Johnson & Johnson Announce Acquisitions to Bolster Respective Oncology Pipelines
January 9th 2024Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its expertise in next generation antibody drug conjugates and targeted oncologic therapies.
CDC Raises Urgent Alert for Low Vaccination Coverage for COVID-19, Influenza, RSV
December 15th 2023CDC data show hospitalizations among all age groups spiked by 200% for influenza, 51% for COVID-19, and 60% for respiratory syncytial virus over the past four weeks, emphasizing the need for improved outreach efforts among at-risk populations.
Prevalence of Eight Chronic Health Conditions Reach Unprecedented Levels in US
December 7th 2023Arthritis, asthma, cancer, cardiovascular diseases, chronic kidney disease, COPD, depression, and diabetes reach the highest recorded levels since the America’s Health Rankings Annual Report began tracking them in 1990.
Roche Bolsters Obesity, Diabetes R&D Portfolio With Acquisition of Carmot Therapeutics
December 4th 2023Roche announces definitive merger agreement to acquire Carmot Therapeutics, Inc., which has an R&D portfolio that includes clinical stage subcutaneous and oral incretins for the treatment of patients with obesity, both with and without diabetes.
What Pharma Fears Most About AI
October 4th 2023In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what pharma fears most about AI.